Inactive Instrument

Biodexa Pharmaceuticals Plc London S.E.

BDRX

GB00BNGF1L75

Biotechnology & Medical Research

Midatech Pharma Plc announced that it has received $7 million in funding from MidCap Financial, LLC, Investment Arm

January 01, 2018

Midatech Pharma Plc announced that it has received a four-year senior secured loan agreement with MidCap Financial, LLC, Investment Arm for gross proceeds of $7,000,000 on January 2, 2018.

Latest news about Biodexa Pharmaceuticals Plc

Biodexa Says Health Canada Approved Phase 2a Tolimidone Study in Type 1 Diabetes	07-16	MT
Biodexa Pharmaceuticals plc Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada	07-16	CI
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	07-15	MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	07-12	MT
Sector Update: Health Care Stocks Rise Late Afternoon	07-11	MT
Sector Update: Health Care	07-11	MT
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	07-11	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	07-11	MT
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar	07-11	MT
Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data	07-11	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	07-10	MT
Biodexa Pharmaceuticals plc Announces Departure of Dmitry Zamoryakhin, Chief Scientific Officer and Chief Medical Officer	07-05	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	07-03	MT
Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024	07-02	CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	07-01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	06-28	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-27	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	06-24	MT
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa? At 12 Months in Familial Adenomatous Polyposis	06-24	CI
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	06-13	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	06-11	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	06-05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	06-04	MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	06-03	MT
Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis	06-03	CI

Chart Biodexa Pharmaceuticals Plc

Duration

Period

More charts

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Sector

Biotechnology & Medical Research

Calendar

2024-09-11 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+24.22%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.87%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs

Biodexa Pharmaceuticals Plc London S.E.

Equities

BDRX

GB00BNGF1L75

Biotechnology & Medical Research

Midatech Pharma Plc announced that it has received $7 million in funding from MidCap Financial, LLC, Investment Arm

Latest news about Biodexa Pharmaceuticals Plc

Chart Biodexa Pharmaceuticals Plc

Company Profile

Sector Bio Therapeutic Drugs